A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: Results from the CAP-IN trial

Chest

Volumn 128, Issue 5, 2005, Pages 3246-3254

  Samsa, Gregory P ^a,c   Matchar, David B ^a   Harnett, James ^b   Wilson, Jerome ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Azithromycin; Community acquired pneumonia; Cost minimization analysis; Levofloxacin; Randomized controlled trial

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; LEVOFLOXACIN;

AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DECISION MAKING; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOME CARE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 28144456685     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.5.3246     Document Type: Article

References (16)

1. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101:508-515
2. Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs. cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch Intern Med 2000; 160:1294-1300
3. Stahl JE, Barza MD, Desfardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576-2580
4. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433
5. Zervos M, Mandell LA, Vrooman PS, et al. Efficacy and safety of intravenous azithromycin plus ceftriaxone versus intravenous levofloxacin with step down oral therapy for the treatment of hospitalized patients with moderate to severe community acquired pneumonia. Respir Med 2005 (in press)
6. Good PI. Resampling methods: a practical guide to data analysis. Boston MA: Birkliauser Publishers, 1999
7. Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 125:1503-1511
8. Dudas V, Hopefl A, Jacobs R, et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34:446-452
9. Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states. Chest 2001; 119:1420-1426
10. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576-2580
11. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-2572
12. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160:1399-1408
13. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24:1292-1308;
14. erratum Clin Ther 2003; 25:1039
15. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mijcoplasma pneumoniae, and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214-221
16. Sanchez F, Mensa J, Martinez JA, et al. Is azithromycin the first choice macrolide for treatment of community-acquired pneumonia. Clin Infect Dis 2003; 36:1239-1245